AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
Total Valuation
AnaptysBio has a market cap or net worth of $1.81B. The enterprise value is $2.74B.
Market Cap$1.81B
Enterprise Value$2.74B
Share Statistics
AnaptysBio has 28,748,255 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,748,255
Owned by Insiders2.28%
Owned by Institutions0.47%
Financial Efficiency
AnaptysBio’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is 14.61%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)14.61%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee1.73M
Profits Per Employee364.81K
Employee Count136
Asset Turnover0.64
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of AnaptysBio is ―. AnaptysBio’s PEG ratio is 0.75.
PE Ratio―
PS Ratio3.83
PB Ratio24.14
Price to Fair Value24.14
Price to FCF45.80
Price to Operating Cash Flow92.73
PEG Ratio0.75
Income Statement
In the last 12 months, AnaptysBio had revenue of 234.60M and earned -13.23M in profits. Earnings per share was -0.46.
Revenue234.60M
Gross Profit232.18M
Operating Income47.90M
Pretax Income-13.07M
Net Income-13.23M
EBITDA50.32M
Earnings Per Share (EPS)-0.46
Cash Flow
In the last 12 months, operating cash flow was 19.70M and capital expenditures -87.00K, giving a free cash flow of 19.61M billion.
Operating Cash Flow19.70M
Free Cash Flow19.61M
Free Cash Flow per Share0.68
Dividends & Yields
AnaptysBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.79
52-Week Price Change354.44%
50-Day Moving Average59.68
200-Day Moving Average40.04
Relative Strength Index (RSI)58.87
Average Volume (3m)627.22K
Important Dates
AnaptysBio upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 3, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
AnaptysBio as a current ratio of 9.07, with Debt / Equity ratio of 781.08%
Current Ratio9.07
Quick Ratio9.07
Debt to Market Cap0.02
Net Debt to EBITDA-4.45
Interest Coverage Ratio0.60
Taxes
In the past 12 months, AnaptysBio has paid 164.00K in taxes.
Income Tax164.00K
Effective Tax Rate-0.01
Enterprise Valuation
AnaptysBio EV to EBITDA ratio is 13.40, with an EV/FCF ratio of 34.37.
EV to Sales2.87
EV to EBITDA13.40
EV to Free Cash Flow34.37
EV to Operating Cash Flow34.22
Balance Sheet
AnaptysBio has $311.64M in cash and marketable securities with $290.64M in debt, giving a net cash position of $21.00M billion.
Cash & Marketable Securities$311.64M
Total Debt$290.64M
Net Cash$21.00M
Net Cash Per Share$0.73
Tangible Book Value Per Share$1.34
Margins
Gross margin is 98.97%, with operating margin of 20.42%, and net profit margin of -5.64%.
Gross Margin98.97%
Operating Margin20.42%
Pretax Margin-5.57%
Net Profit Margin-5.64%
EBITDA Margin21.45%
EBIT Margin20.42%
Analyst Forecast
The average price target for AnaptysBio is $78.45, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$78.45
Price Target Upside16.21% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast157.01%
EPS Growth Forecast94.31%